Phase 3 Trial ATX-101 (BELKYRA) Published by JAAD
You may have read over the past year about Dr Humphrey’s involvement in the new groundbreaking treatment, Belkyra (Kybella in the US). Dr Shannon Humphrey was lead investigator during the phase III trials, which ultimately lead to FDA and Health Canada approval. We are incredibly proud of Dr Humphrey’s contributions to medical science.
The Journal of the American Academy of Dermatology (JAAD) has reviewed and published the phase III randomized control trial. A significant achievement for Dr Humphrey and our Clinical Research practice.
The Journal of the American Academy of Dermatology (JAAD), is the official scientific publication of the American Academy of Dermatology (AAD). This noteworthy journal is the specialty’s leading publication and features original, peer-reviewed articles with a focus on clinical, investigative studies as well as innovative treatments (many other areas as well). The JAAD ensures content provided to readers offers only evidence-based recommendations in an effort to advance the community and profession – in turn improving the practice for our patients.
The Journal is ranked 3rd of 61 journals in the Dermatology category in the 2014 Journal Citation Reports®, published by Thomson Reuters, and has an Impact Factor of 4.449.
Should you be interested in reviewing the study – you can find it here.
